By acquiring the global rights to NRP104, New River Pharmaceuticals' Phase III ADHD treatment, Shire Pharmaceuticals has effectively licensed a successor to its market-leading ADHD drug, Adderall XR#8482; (extended-release mixed amphetamine salts). However, some analysts have expressed concern that Shire is not looking to diversify away from this therapy area.